ImpriMed raises $10m Series A2 bridge for precision medicine
LB Investment led the round as ImpriMed advances U.S. commercialization and expands in Asia.
Testing cancer cells to inform treatment choices
ImpriMed analyzes living cancer cells from a patient against a panel of drugs, then combines those response measurements with genomic, immunophenotypic and clinical data to help inform treatment selection. The company currently provides its Drug Response Predictions service to veterinary oncologists treating canine and feline blood cancers, and is developing a broader human precision-medicine business.
The Series A2 bridge will support U.S. commercialization and expansion in Asia. ImpriMed says it is preparing U.S. products for blood cancers and blood infections, with FDA clearance and CLIA certification targeted for 2027.
Use of funds
Advance U.S. commercialization
Expand in Asia